人民日报关注：新一批药品集采规则优化 “反内卷”发挥作用

Core Insights - The eleventh batch of national organized drug procurement results is about to be officially announced, with new rules focusing on "stabilizing clinical use, ensuring quality, preventing internal competition, and avoiding collusion" [1] - A total of 272 companies with 55 varieties and 453 products have obtained the proposed selection qualification, increasing the total number of drugs included in national organized procurement to 490 [1][2] - The new procurement rules emphasize quality control and have raised the quality threshold for companies, ensuring that selected drugs meet stringent quality standards [2][4] Group 1: Procurement Process and Results - The types of drugs included in this procurement cover common medications for chronic and major diseases, including anti-infectives, anti-tumor drugs, and cardiovascular medications [2] - 77% of the 46,000 medical institutions reported quantities based on specific brands, allowing patients to access lower-priced drugs without changing their usual brands [2] - 75% of the procurement requests from medical institutions were met, with a diverse range of selected products from multiple companies across different regions [2][3] Group 2: Quality Control and Competition - The new rules have increased the quality control requirements for companies, including a two-year compliance history with GMP standards and no recent quality failures [2][4] - The introduction of a "reference price" mechanism aims to prevent extreme low pricing and encourages rational bidding among companies [5][6] - The competitive environment has intensified, with some products seeing bids significantly lower than the average price, yet the new rules allow for a balanced selection process [6][8] Group 3: Industry Challenges and Future Directions - The procurement system aims to reduce medication costs for insured individuals while promoting a shift in the generic drug industry towards quality and innovation [7] - Concerns remain about the potential impact of low-profit margins on drug quality and the overall sustainability of the industry [7][9] - Experts suggest that future procurement rules should continue to evolve, focusing on guiding companies in scientific project selection to prevent excessive competition in similar drug categories [9]